FibroScan®
by echosens

The non-invasive gold standard solution for comprehensive management of liver health

FibroScan® by echosens

FibroScan® Expert 630
The complete non-invasive solution for advanced liver disease management

Powered by LSM by VCTE™, CAP™ and SSM by VCTE™ as part of an overall assessment of the liver

- Expanded clinical capabilities with spleen stiffness measurement
- Enhanced exam efficiency with high-speed processing
- Embedded ultrasound guidance eases both liver and spleen targeting

SSM by VCTE™ is only available on the FibroScan® Expert 630 model

FibroScan® Compact 530
The portable non-invasive solution for efficient liver disease management

Powered by LSM by VCTE™ and CAP™

- Adaptive design and ergonomics for any point-of-care setting: from cart-based to transportable

FibroScan® Mini+ 430
The mobile non-invasive solution for liver disease management, ideal for multi-site configuration

Powered by LSM by VCTE™ and CAP™

- Designed for multi-site sharing and near-patient testing
- Winner of the Red Dot Design Award

FibroScan® Mini+ 430 or FibroScan® Mini 430: product name may differ depending on country

---

FibroScan® is powered by **three unique, patented and validated biomarkers** to quickly and easily assess liver health.

Our solutions enable non-invasive diagnosis and monitoring at the point-of-care.

LSM by VCTE™
Liver fibrosis assessment

3,800+ publications

The standard for the non-invasive evaluation of liver stiffness.[1]

3,800+ peer-reviewed publications support the use of LSM by VCTE™.

Relevant in all Chronic Liver Diseases.

CAP™
Liver steatosis assessment

1,130+ publications

1,130+ peer-reviewed publications support the use of CAP™.

Relevant in Steatotic Liver Diseases: MASLD, MASH, MetALD and ALD.

SSM by VCTE™
Portal hypertension assessment and variceal surveillance*

134+ publications

134+ peer-reviewed publications support the use of SSM by VCTE™.

Relevant in the management and risk stratification of patients with advanced chronic liver disease.[2,3,4]

* SSM is a marker for non-invasive evaluation of spleen stiffness which has been used in a clinical setting to assess portal hypertension and for variceal surveillance.

FibroScan® probes
Optimize measurement accuracy on all patient morphologies

S+ Probe

For pediatric population

Designed for being placed into narrow intercostal space

M+ Probe

For patients with standard morphotype

Probe compatible with Guided VCTE™

XL+ Probe

For patients with obesity and extreme obesity

Designed to enhance signal penetration through deeper tissues

Probe compatible with Guided VCTE™

Related products

Liver Health Management solutions

LiverHealth MANAGEMENT

Advancing Liver Health Management for all

Echosens introduces the Liver Health Management platform, an innovative cloud-based solution that helps clinicians provide accessible longitudinal liver care for their patients.

By helping clinicians and their patients take greater control of liver disease, we aspire to improve liver health for everyone. Echosens developed an ecosystem of solutions to support clinical decisions for physicians.

LHM platform is currently available in some countries. Contact us to find out if LHM platform is available in your country or when it will be launched.

Scores FibroScan based

Enhancing FibroScan® liver disease assessment with biological markers

Fast
Identification of patients with at-risk MASH

Agile 3+
Identification of advanced fibrosis in patients with MASLD

Agile 4
Identification of cirrhosis in patients with MASLD

myFibroScan

Your FibroScan® companion with Echosens Scores and Interpretation Guide

Available on myfibroscan.com and applications

FibroScan gateway by echosens

Real-time secure transfer of exam results to your EHR

NEW

Guided VCTE™
Seamless liver health assessment for all

Intuitive features for faster examinations and simplified scanning[5]

- Two new indicators that allow for quick identification of the optimal measurement location
- AutoScan feature which triggers 10 valid measurements through a single click
- SmartExam features fully included: SmartDepth and Continuous CAP™

Stiffness indicator

CAP™ indicator



Renowned Publication Presence
& Endorsement in Clinical Practice Guidelines

4,200+ peer-reviewed publications

180+ international guidelines

More than 4,200 peer-reviewed publications and 180 international guidelines advocate the use of FibroScan® as the reference non-invasive solution for liver fibrosis, cirrhosis, and steatosis assessment **across all etiologies of chronic liver disease (viral hepatitis, MASLD/MASH, alcoholic liver disease).**[4,6,7]

AASLD · ADA · AHA · APASL · EASL · AACE · AGA · AISF · Baveno VII · NICE Guidance

Examinations with FibroScan® can inform treatment decisions across the spectrum of disease



FibroScan® by echosens

Next Generation FibroScan®

The non-invasive gold standard solution for comprehensive management of liver health

Which FibroScan® is right for you?

FibroScan® mini+ 430 by echosens

FibroScan® compact 530 by echosens

FibroScan® expert 630 by echosens

		mini+ 430	compact 530	expert 630
Capabilities	Guided VCTE™ SmartExam features fully included	●	●	●
	LSM by VCTE™	●	●	●
	CAP™	●	●	●
	SSM by VCTE™			●
Features	LHM compatibility	●	●	●
	FibroScan® Gateway compatibility	●	●	●
	myFibroScan® compatibility	●	●	●
	Two probe connectors to easily switch between probes during the examination	●	●	●
	Embedded ultrasound localization system			●
	High-speed processing			●
	Integrated barcode reader			●
Ergonomics	Fully transportable	●	●	
	Battery-powered	●	●	
	Airplane-compatible suitcase	●		
	Option: roll stand		●	
	Weight	11 lbs. / 5 kg	22 lbs. / 10 kg	101 lbs. / 46 kg

Dedicated customer service and support
We will support you with a full range of services: technical support, probe calibrations, maintenance and more.

Interested in FibroScan® for your practice?
Contact us on echosens.com

LSM: Liver Stiffness Measurement / SSM: Spleen Stiffness Measurement / CAP™: Controlled Attenuation Parameter / VCTE™: Vibration-Controlled Transient Elastography / MASLD: Metabolic dysfunction-associated steatotic liver disease (formerly known as NAFLD) / MASH: Metabolic dysfunction-associated steatohepatitis (formerly known as NASH) / MetALD: MASLD and increase alcohol intake / ALD: Alcohol-associated liver disease / MASLD-MASH formerly known as NAFLD-NASH / LHM: Liver Health Management

References

1. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006. **2.** Stefanescu H, *et al.* A novel spleen-dedicated stiffness measurement by FibroScanR improves the screening of high-risk oesophageal varices. Liver Int. 2020;40(1):175-185. doi:10.1111/liv.14228. **3.** Dajti, Elton *et al.* "A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease." The American journal of gastroenterology vol. 117,11 (2022): 1825-1833. doi:10.14309/ajg.0000000000001887. **4.** Baveno VII – R. de Franchis *et al.* Renewing consensus in portal hypertension. Journal of hepatology vol. 76,4 (2022): 959-974. doi:10.1016/j.jhep.2021.12.022. **5.** Based on internal data. E431R020.1. **6.** European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu *et al.* "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update." Journal of hepatology vol. 75,3 (2021): 659-689. **7.** Kanwal, Fasiha *et al.* "Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease." Gastroenterology vol. 161,5 (2021): 1657-1669.